At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
Medpage Today on MSN3d
Which High-Risk Patients Should Get the RSV Vaccine?The shift to a clear recommendation for vaccination goes beyond the prior guidance "just to encourage adults to talk to their ...
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...
given in combination with Merck’s anti-PD-1 therapy KEYTRUDA. These data, as well as new pre-clinical data from IO Biotech’s second vaccine candidate, IO112, will be presented at the Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback